Fingolimod Induced Fulminant Liver Failure Requiring Liver Transplantation: A Case Report

Overview

Journal Hepatol Forum

Publisher Kare Publishing

Specialty Gastroenterology

Date 2023 May 30

PMID 37250929

Authors

Ali Riza Caliskan

Muhsin Murat Muhip Harputluoglu

Emine Samdanci

Salih Cirik

Sezai Yilmaz

Affiliations

Soon will be listed here.

Abstract

Fingolimod has been used for about ten years to treat multiple recurrent sclerosis. It has been reported that Fingolimod causes an elevation in liver enzymes. In this case report, the clinical and laboratory parameters improved after discontinuation of the drug. However, there is no publication in the literature regarding acute liver failure and liver transplantation following Fingolimod treatment. In this article, we presented a 33 - year - old female patient who developed acute liver failure and underwent liver transplantation after Fingolimod treatment for recurrent multiple sclerosis.

Citing Articles

Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis.

Ramos-Molina B, Rossell J, Perez-Montes de Oca A, Pardina E, Genua I, Rojo-Lopez M Front Endocrinol (Lausanne). 2024; 15:1400961.

PMID: 38962680 PMC: 11220194. DOI: 10.3389/fendo.2024.1400961.

References

Lee W, Squires Jr R, Nyberg S, Doo E, Hoofnagle J . Acute liver failure: Summary of a workshop. Hepatology. 2008; 47(4):1401-15. PMC: 3381946. DOI: 10.1002/hep.22177. View

Cohen J, Khatri B, Barkhof F, Comi G, Hartung H, Montalban X . Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2015; 87(5):468-75. PMC: 4853559. DOI: 10.1136/jnnp-2015-310597. View

Lee W, Stravitz R, Larson A . Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012; 55(3):965-7. PMC: 3378702. DOI: 10.1002/hep.25551. View

Yamout B, Zeineddine M, Tamim H, Khoury S . Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East. J Neuroimmunol. 2015; 289:93-7. DOI: 10.1016/j.jneuroim.2015.10.015. View

Tullman M . Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013; 19(2 Suppl):S15-20. View

Cohen J, Barkhof F, Comi G, Hartung H, Khatri B, Montalban X . Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):402-15. DOI: 10.1056/NEJMoa0907839. View

Hofmann M, Brinkmann V, Zerwes H . FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol. 2006; 6(13-14):1902-10. DOI: 10.1016/j.intimp.2006.07.030. View

Calabresi P, Radue E, Goodin D, Jeffery D, Rammohan K, Reder A . Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(6):545-56. DOI: 10.1016/S1474-4422(14)70049-3. View

Lee W . Etiologies of acute liver failure. Semin Liver Dis. 2008; 28(2):142-52. DOI: 10.1055/s-2008-1073114. View

10.

Kappos L, Cohen J, Collins W, de Vera A, Zhang-Auberson L, Ritter S . Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Mult Scler Relat Disord. 2015; 3(4):494-504. DOI: 10.1016/j.msard.2014.03.002. View

11.

Kappos L, Radue E, OConnor P, Polman C, Hohlfeld R, Calabresi P . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401. DOI: 10.1056/NEJMoa0909494. View

12.

Sospedra M, Martin R . Immunology of multiple sclerosis. Annu Rev Immunol. 2005; 23:683-747. DOI: 10.1146/annurev.immunol.23.021704.115707. View

13.

Antonazzo I, Poluzzi E, Forcesi E, Riise T, Bjornevik K, Baldin E . Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Mult Scler. 2018; 25(12):1633-1640. DOI: 10.1177/1352458518799598. View

14.

Lu M, Shih Y, Hsieh T, Lin J . Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis. J Formos Med Assoc. 2019; 119(4):886-887. DOI: 10.1016/j.jfma.2019.10.012. View

15.

Faissner S, Gold R . Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. CNS Drugs. 2018; 32(3):269-287. DOI: 10.1007/s40263-018-0488-6. View